# Clinical Trial Compliance Analysis Report

**Generated:** 2026-01-05 12:53:37

## Document Information

- **Protocol:** protocol_001_diabetes_phase3.txt
- **Requirements:** requirements_diabetes_study.txt

## Executive Summary

### Overall Compliance: 17.2% ðŸ”´ **LOW COMPLIANCE**

| Metric | Count | Percentage |
|--------|-------|------------|
| **Total Requirements** | 32 | 100% |
| âœ… Followed | 5 | 15.6% |
| âš ï¸ Partial | 1 | 3.1% |
| âŒ Not Followed | 19 | 59.4% |
| âž– Not Applicable | 7 | 21.9% |

## Key Findings

âš ï¸ **19 requirement(s) not followed** - These require immediate attention.

âš ï¸ **1 requirement(s) partially met** - These may need clarification or modification.

---

## Detailed Requirements Analysis

### âŒ Requirements Not Followed

*Found 19 requirement(s) in this category*

#### 1. The study must be randomized and double-blind to minimize bias.

**Full Requirement:**
> The study must be randomized and double-blind to minimize bias.

**Confidence Score:** 90%

**Analysis:**
The protocol specifies that it is an 'open-label, single-arm study,' which indicates that it is not randomized or double-blind. This design does not meet the requirement to minimize bias, as participants and investigators are aware of the treatment being administered.

*Based on 8 relevant protocol section(s)*

---

#### 2. A placebo control arm must be included for efficacy comparison.

**Full Requirement:**
> A placebo control arm must be included for efficacy comparison.

**Confidence Score:** 90%

**Analysis:**
The protocol describes a Phase 2, open-label, single-arm study, which indicates that there is no placebo control arm included for efficacy comparison. The requirement for a placebo control arm is therefore not met, as the study design does not incorporate a control group for comparison.

*Based on 8 relevant protocol section(s)*

---

#### 3. The study duration must be at least 52 weeks to assess long-term glycemic control.

**Full Requirement:**
> The study duration must be at least 52 weeks to assess long-term glycemic control.

**Confidence Score:** 90%

**Analysis:**
The protocol does not specify a minimum study duration of 52 weeks to assess long-term glycemic control. Instead, it outlines a treatment period until disease progression or unacceptable toxicity, with a follow-up period of 12 weeks after the last dose, which does not meet the requirement.

*Based on 8 relevant protocol section(s)*

---

#### 4. Stratified randomization should be used based on baseline HbA1c levels.

**Full Requirement:**
> Stratified randomization should be used based on baseline HbA1c levels.

**Confidence Score:** 90%

**Analysis:**
The protocol does not mention the use of stratified randomization based on baseline HbA1c levels. While it provides details on sample size, analysis populations, and other study design elements, there is no indication that stratification will occur, which is a key component of the requirement.

*Based on 8 relevant protocol section(s)*

---

#### 5. Pregnant or breastfeeding women must be excluded.

**Full Requirement:**
> Pregnant or breastfeeding women must be excluded.

**Confidence Score:** 90%

**Analysis:**
The protocol does not explicitly mention any exclusion criteria related to pregnant or breastfeeding women. Without this information, it cannot be confirmed that the requirement is met.

*Based on 8 relevant protocol section(s)*

---

#### 6. Primary endpoint must be change in HbA1c from baseline.

**Full Requirement:**
> Primary endpoint must be change in HbA1c from baseline.

**Confidence Score:** 90%

**Analysis:**
The protocol does not specify a primary endpoint related to the change in HbA1c from baseline. Instead, it focuses on evaluating the efficacy of the immunotherapy agent IMB-4521 in patients with advanced NSCLC, with endpoints related to overall response rate (ORR) rather than HbA1c levels.

*Based on 8 relevant protocol section(s)*

---

#### 7. Secondary endpoints should include fasting plasma glucose changes.

**Full Requirement:**
> Secondary endpoints should include fasting plasma glucose changes.

**Confidence Score:** 90%

**Analysis:**
The protocol does not mention fasting plasma glucose changes as a secondary endpoint. While it includes various biomarker assessments and statistical considerations, there is no reference to glucose measurements, indicating that this requirement is not met.

*Based on 8 relevant protocol section(s)*

---

#### 8. Proportion of patients achieving HbA1c target of <7% must be assessed.

**Full Requirement:**
> Proportion of patients achieving HbA1c target of <7% must be assessed.

**Confidence Score:** 90%

**Analysis:**
The protocol does not mention the assessment of the proportion of patients achieving an HbA1c target of <7%. The focus is primarily on the efficacy and safety of the immunotherapy agent IMB-4521 in patients with advanced NSCLC, without any reference to HbA1c targets or related assessments.

*Based on 8 relevant protocol section(s)*

---

#### 9. Body weight changes must be monitored as a secondary endpoint.

**Full Requirement:**
> Body weight changes must be monitored as a secondary endpoint.

**Confidence Score:** 90%

**Analysis:**
The protocol does not mention monitoring body weight changes as a secondary endpoint. While it includes various assessments related to tumor characteristics and safety, there is no indication that body weight is being tracked, which directly contradicts the requirement.

*Based on 8 relevant protocol section(s)*

---

#### 10. All adverse events must be collected and coded using MedDRA.

**Full Requirement:**
> All adverse events must be collected and coded using MedDRA.

**Confidence Score:** 90%

**Analysis:**
The protocol does not mention the collection and coding of adverse events using MedDRA, which is a specific requirement. Therefore, it is assessed as not followed. However, the absence of this information could be due to a lack of detail in the provided sections.

*Based on 8 relevant protocol section(s)*

---

#### 11. Pancreatic enzymes (amylase and lipase) must be monitored regularly.

**Full Requirement:**
> Pancreatic enzymes (amylase and lipase) must be monitored regularly.

**Confidence Score:** 90%

**Analysis:**
The protocol does not mention any requirement for the regular monitoring of pancreatic enzymes such as amylase and lipase. Therefore, the requirement is not met, as there is no indication that these specific biomarkers will be monitored during the study.

*Based on 8 relevant protocol section(s)*

---

#### 12. 12-lead ECG must be performed at baseline and key timepoints.

**Full Requirement:**
> 12-lead ECG must be performed at baseline and key timepoints.

**Confidence Score:** 90%

**Analysis:**
The protocol does not mention the requirement for performing 12-lead ECGs at baseline or key timepoints, indicating that this requirement is not met. The absence of any reference to ECG assessments suggests that the protocol does not address this critical aspect of monitoring in the study.

*Based on 8 relevant protocol section(s)*

---

#### 13. Vital signs including blood pressure and heart rate must be recorded at each visit.

**Full Requirement:**
> Vital signs including blood pressure and heart rate must be recorded at each visit.

**Confidence Score:** 90%

**Analysis:**
The protocol does not mention the recording of vital signs, including blood pressure and heart rate, at each visit. Therefore, the requirement is not met. The absence of this information suggests that the protocol does not comply with the specified requirement.

*Based on 8 relevant protocol section(s)*

---

#### 14. Laboratory assessments must include complete blood count and comprehensive metabolic panel.

**Full Requirement:**
> Laboratory assessments must include complete blood count and comprehensive metabolic panel.

**Confidence Score:** 90%

**Analysis:**
The protocol does not mention any laboratory assessments, including complete blood count or comprehensive metabolic panel, which are explicitly required. Therefore, the requirement is not met.

*Based on 8 relevant protocol section(s)*

---

#### 15. Electronic Data Capture (EDC) system must be used.

**Full Requirement:**
> Electronic Data Capture (EDC) system must be used.

**Confidence Score:** 90%

**Analysis:**
The protocol does not mention the use of an Electronic Data Capture (EDC) system, which is a specific requirement. While the protocol outlines various aspects of the study, it lacks any reference to the data management or capture methods, indicating that this requirement is not met.

*Based on 8 relevant protocol section(s)*

---

#### 16. Query management must be implemented for data quality.

**Full Requirement:**
> Query management must be implemented for data quality.

**Confidence Score:** 80%

**Analysis:**
The protocol does not explicitly mention any query management processes for data quality. While it includes sections on informed consent, data safety monitoring, and independent reviews, there is no indication of a systematic approach to managing queries related to data quality, which is essential for ensuring the integrity of the study data.

*Based on 8 relevant protocol section(s)*

---

#### 17. Database lock procedures must be defined.

**Full Requirement:**
> Database lock procedures must be defined.

**Confidence Score:** 90%

**Analysis:**
The protocol does not include any specific procedures or details regarding database lock procedures. While it covers various aspects of the study, such as informed consent and safety monitoring, the absence of a defined database lock process means the requirement is not met.

*Based on 8 relevant protocol section(s)*

---

#### 18. Per-protocol analysis should be conducted as sensitivity analysis.

**Full Requirement:**
> Per-protocol analysis should be conducted as sensitivity analysis.

**Confidence Score:** 80%

**Analysis:**
The protocol does not explicitly mention that a per-protocol analysis will be conducted as a sensitivity analysis. While it outlines different analysis populations, including Intent-to-Treat and Efficacy-Evaluable, there is no reference to a per-protocol analysis being part of the sensitivity analysis, which is a specific requirement.

*Based on 8 relevant protocol section(s)*

---

#### 19. IRB/EC approval must be obtained before study initiation.

**Full Requirement:**
> IRB/EC approval must be obtained before study initiation.

**Confidence Score:** 80%

**Analysis:**
The protocol does not explicitly mention obtaining IRB/EC approval prior to study initiation. While it includes sections on informed consent and ethical considerations, there is no clear statement confirming that IRB/EC approval has been obtained, which is a critical requirement.

*Based on 8 relevant protocol section(s)*

---

### âš ï¸ Partially Met Requirements

*Found 1 requirement(s) in this category*

#### 1. Patients must have adequate time to consider participation.

**Full Requirement:**
> Patients must have adequate time to consider participation.

**Confidence Score:** 80%

**Analysis:**
The protocol includes a section on informed consent, stating that subjects must have the opportunity to ask questions and must sign the consent form voluntarily. However, it does not specify the exact time frame or duration that patients will have to consider participation, which is crucial for fully meeting the requirement.

*Based on 8 relevant protocol section(s)*

---

### âœ… Fully Compliant Requirements

*Found 5 requirement(s) in this category*

#### 1. Written informed consent must be obtained before any study procedures.

**Full Requirement:**
> Written informed consent must be obtained before any study procedures.

**Confidence Score:** 100%

**Analysis:**
The protocol clearly states in Section 10.1 that written informed consent must be obtained before any study-specific procedures. This requirement is explicitly addressed and aligns with the regulatory standards for obtaining informed consent in clinical trials.

*Based on 8 relevant protocol section(s)*

---

#### 2. Consent process must follow ICH-GCP guidelines.

**Full Requirement:**
> Consent process must follow ICH-GCP guidelines.

**Confidence Score:** 100%

**Analysis:**
The protocol clearly states that written informed consent must be obtained before any study-specific procedures, allowing subjects the opportunity to ask questions and ensuring that consent is given voluntarily. This aligns with ICH-GCP guidelines for the informed consent process.

*Based on 8 relevant protocol section(s)*

---

#### 3. Intent-to-treat analysis must be the primary analysis population.

**Full Requirement:**
> Intent-to-treat analysis must be the primary analysis population.

**Confidence Score:** 100%

**Analysis:**
The protocol clearly states that the Intent-to-Treat (ITT) population includes all enrolled subjects who receive at least one dose, which aligns with the requirement for ITT analysis to be the primary analysis population. There are no contradictions or omissions regarding this requirement in the protocol.

*Based on 8 relevant protocol section(s)*

---

#### 4. Sample size must provide at least 90% power for primary endpoint.

**Full Requirement:**
> Sample size must provide at least 90% power for primary endpoint.

**Confidence Score:** 100%

**Analysis:**
The protocol specifies that with 180 subjects, the study has 90% power to detect an objective response rate (ORR) of 30% compared to a null hypothesis of 20%. This clearly meets the requirement for the sample size to provide at least 90% power for the primary endpoint.

*Based on 8 relevant protocol section(s)*

---

#### 5. Study must comply with applicable regulatory requirements.

**Full Requirement:**
> Study must comply with applicable regulatory requirements.

**Confidence Score:** 100%

**Analysis:**
The protocol includes sections on informed consent, data safety monitoring, and independent review processes, which are essential for compliance with regulatory requirements. Additionally, the study design and statistical considerations are clearly outlined, indicating adherence to applicable regulations.

*Based on 8 relevant protocol section(s)*

---

### âž– Non-Applicable Requirements

*Found 7 requirement(s) in this category*

#### 1. Patients must have confirmed Type 2 Diabetes Mellitus diagnosis for at least 6 months.

**Full Requirement:**
> Patients must have confirmed Type 2 Diabetes Mellitus diagnosis for at least 6 months.

**Confidence Score:** 90%

**Analysis:**
The protocol does not mention any requirements related to Type 2 Diabetes Mellitus, as it focuses solely on patients with advanced non-small cell lung cancer (NSCLC). Therefore, the requirement regarding diabetes diagnosis is not applicable to this study.

*Based on 8 relevant protocol section(s)*

---

#### 2. Baseline HbA1c must be between 7.0% and 10.5% inclusive.

**Full Requirement:**
> Baseline HbA1c must be between 7.0% and 10.5% inclusive.

**Confidence Score:** 90%

**Analysis:**
The protocol does not specify any inclusion or exclusion criteria related to baseline HbA1c levels, which means the requirement regarding HbA1c levels is not applicable to this study. The focus of the protocol is on advanced non-small cell lung cancer and its treatment, without mention of diabetes or HbA1c measurements.

*Based on 8 relevant protocol section(s)*

---

#### 3. Patients must be on stable metformin therapy (minimum 1500 mg/day) for at least 8 weeks.

**Full Requirement:**
> Patients must be on stable metformin therapy (minimum 1500 mg/day) for at least 8 weeks.

**Confidence Score:** 90%

**Analysis:**
The protocol does not specify any requirements regarding metformin therapy or its dosage, making the requirement not applicable to this study. The focus of the protocol is on the efficacy and safety of the immunotherapy agent IMB-4521 in patients with advanced NSCLC, without mention of metformin or its use.

*Based on 8 relevant protocol section(s)*

---

#### 4. BMI should be between 25 and 45 kg/mÂ².

**Full Requirement:**
> BMI should be between 25 and 45 kg/mÂ².

**Confidence Score:** 90%

**Analysis:**
The protocol does not specify any inclusion or exclusion criteria related to BMI, which means the requirement regarding BMI being between 25 and 45 kg/mÂ² is not applicable to this study. Therefore, it cannot be assessed for compliance.

*Based on 8 relevant protocol section(s)*

---

#### 5. Patients with Type 1 diabetes must be excluded.

**Full Requirement:**
> Patients with Type 1 diabetes must be excluded.

**Confidence Score:** 90%

**Analysis:**
The protocol does not mention any exclusion criteria related to Type 1 diabetes, nor does it focus on patients with diabetes in general. Since the study is specifically designed for patients with advanced non-small cell lung cancer (NSCLC), the requirement regarding Type 1 diabetes exclusion is not applicable to this protocol.

*Based on 8 relevant protocol section(s)*

---

#### 6. Patients with history of pancreatitis must be excluded for GLP-1 agonist studies.

**Full Requirement:**
> Patients with history of pancreatitis must be excluded for GLP-1 agonist studies.

**Confidence Score:** 90%

**Analysis:**
The protocol does not mention any exclusion criteria related to patients with a history of pancreatitis, which is a specific requirement for GLP-1 agonist studies. However, since this study focuses on a PD-L1 inhibitor for non-small cell lung cancer, the requirement does not apply to this protocol.

*Based on 8 relevant protocol section(s)*

---

#### 7. All protocol amendments must be approved before implementation.

**Full Requirement:**
> All protocol amendments must be approved before implementation.

**Confidence Score:** 90%

**Analysis:**
The protocol does not explicitly mention the process for approving protocol amendments, which is critical for determining compliance with the requirement. However, the sections provided focus on informed consent, safety monitoring, and study design, without addressing amendment approval, leading to the conclusion that this requirement does not apply to the current protocol.

*Based on 8 relevant protocol section(s)*

---

## Recommendations

### Critical Actions Required

1. **Address 19 non-compliant requirement(s)**
   - Review protocol sections related to these requirements
   - Consider protocol amendments if necessary
   - Document justification if requirements cannot be met

### Recommended Actions

1. **Clarify 1 partially met requirement(s)**
   - Review specific gaps identified in the analysis
   - Enhance protocol documentation where needed
   - Seek stakeholder approval for partial compliance

---

## Analysis Metadata

- **Analysis Date:** 2026-01-05 12:53:37
- **Protocol Document:** `data/protocols/protocol_001_diabetes_phase3.txt`
- **Requirements Document:** `data/requirements/requirements_diabetes_study.txt`
- **Analysis Method:** LangChain-powered LLM analysis with vector retrieval
- **Requirements Analyzed:** 32

---

*Generated by Clinical Trial Protocol Matcher - LangChain + DeepSeek*
